About Genaera
Genaera was a Healthcare company based in Plymouth Meeting (United States) founded in 1987. It develops small molecule drugs for type 2 diabetes and obesity. It operates on a B2B model. The company is recorded as dissolved. Its focus areas include Pharmaceuticals, Drug Development and Diabetes and Obesity Treatments. Its competitors include NGM Biopharmaceuticals, MannKind Corp and Rhythm Pharmaceuticals; 3 of its 3 listed competitors have raised funding.
Company details
Genaera, established in 1987, excels in providing healthcare solutions, producing pharmaceutical products, drug development, and diabetes and obesity treatments. Develops small molecule drugs for type 2 diabetes and obesity. Committed to advancing standards, it focuses on innovation, efficiency, and delivering value to clients worldwide.
- Headquarters Plymouth Meeting, United States
- SectorsHealthcare
- Website genaera.com
- Latest Funding Round$25.1M (USD), Post-IPO
May 2006
- InvestorsOch-Ziff Capital Management
& 1 more
Funding Insights of Genaera
- Total Rounds 6
- Last Round Post-IPO — $25.1M
- First Round $7M
(May 2002)
- Investors Count 2
All 6 funding rounds of Genaera with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2006 | $25.1M | Post-IPO | – | – | – |
| Sep 2005 | $24.5M | Post-IPO | – | – | – |
| Oct 2003 | $8.5M | Post-IPO | – | – | – |
| Oct 2003 | $14.4M | Post-IPO | – | – | – |
| May 2003 | $5M | Post-IPO | – | – | |
| May 2002 | $7M | Post-IPO | – | – | – |
2 investors in total: 2 institutional.
Investors in Genaera
Genaera has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Och-Ziff Capital Management and BVF Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
US private equity investments are managed by BVF Partners. | bvflp.com | San Francisco, United States | ||
Diversified investment management services are provided by the firm. | 1999 | ozcap.com | New York, United States |
Investor details for Genaera
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Genaera
3 dated milestones of Genaera across 19 years, from founding to its latest funding, stage changes and deals.
- Founded Genaera is founded.
- Funding First funding round of $7.0M.
- Funding Latest funding round, Post-IPO, of $25.1M.
Competitors of Genaera
Genaera has 3 listed competitors in our database, 3 of them funded. They include NGM Biopharmaceuticals, MannKind Corp and Rhythm Pharmaceuticals.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ngmbio.com | 2007 | San Francisco, United States | $358.87M | 225 | Biologics are developed for cardio-metabolic and liver diseases. | |
| mannkindcorp.com | 1991 | Los Angeles, United States | $50M | 322 | Developer of small-molecule drugs | |
| rhythmtx.com | 2010 | Boston, United States | $84M | 115 | Developer of peptide therapeutics for the treatment of rare genetic deficiencies |
Detailed competitors of Genaera
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Genaera
Websites that share an audience with Genaera (genaera.com).
Websites whose visitors overlap most with Genaera. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| arqule.com | 100% | View details | |||
| onyx-pharm.com | 81% | View details |
Top companies in Diabetes
3 companies that operate in the same segment as Genaera (Diabetes) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of devices for continuous glucose monitoring and manual insulin delivery | 2008 | San Diego, California, United States | USD 100.73 M | USD 1.02 B | 2,650 | |
Wearable glucose monitoring patches are provided for real-time data tracking. | 1999 | San Diego, California, United States | USD 52.5 M | USD 4.66 B | 10,300 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Genaera
Genaera was founded in 1987 and raised its 1st funding round 15 years after it was founded.
Genaera is headquartered in Plymouth Meeting, United States. It is registered at Plymouth Meeting, Pennsylvania, United States.
Genaera, established in 1987, excels in providing healthcare solutions, producing pharmaceutical products, drug development, and diabetes and obesity treatments. Develops small molecule drugs for type 2 diabetes and obesity. Committed to advancing standards, it focuses on innovation, efficiency, and delivering value to clients worldwide.
Genaera's top competitors include Rhythm Pharmaceuticals, MannKind Corp and NGM Biopharmaceuticals.
Genaera has 2 investors. Key investors include Och-Ziff Capital Management, and BVF Partners.